Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 0.52% on January 19, 2025, underperforming the CSI 300 index by 0.57 percentage points, ranking 28th among 31 sub-industries [4]. - Notable performers within the pharmaceutical sub-industries included offline pharmacies (+2.39%) and blood products (+0.11%), while sectors such as medical R&D outsourcing (-1.77%) and vaccines (-1.10%) lagged behind [4]. - Takeda's new drug Oveporexton has received acceptance for its market application in China, targeting narcolepsy type 1 (NT1) and showing promising results in clinical trials [5]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceuticals: Neutral [3]
太平洋医药日报（20260119）：武田Oveporexton在华申报上市
Tai Ping Yang Zheng Quan·2026-01-20 05:45